Vyleesi EMA vs FDA Approach: How Bremelanotide Regulation Differs Across Agencies

FDA Approval: The RECONNECT Trials and the Path to NDA 210557

The FDA based its June 2019 approval on two replicate, randomized, double-blind, placebo-controlled Phase III trials known collectively as RECONNECT. These studies enrolled 1,247 premenopausal women with acquired, generalized HSDD who self-administered bremelanotide 1.75 mg or placebo subcutaneously on an as-needed basis over 24 weeks [1].

Co-Primary Endpoints

Both studies used co-primary endpoints: change from baseline in the number of satisfying sexual events (SSEs) per month and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. Bremelanotide produced a statistically significant increase of approximately 0.5 SSEs per month above placebo and a reduction of roughly 0.7 points on the FSDS-DAO Item 13 (personal distress about low sexual desire) compared to placebo [1]. The effect sizes were modest but consistent across both trials.

FDA Advisory Committee Vote

The Bone, Reproductive and Urologic Drugs Advisory Committee voted in favor of approval, though committee members noted the small absolute treatment effect. Dr. Julia Johnson, who chaired the advisory panel discussion, stated: "The clinical meaningfulness of the effect is something the agency will need to weigh against the totality of the safety data, particularly the cardiovascular findings" [2]. The FDA ultimately determined that even modest benefit was clinically meaningful for a condition with limited treatment options, given an acceptable safety profile within the labeled population.

Label Restrictions the FDA Imposed

The approved label carries several notable restrictions. Vyleesi is limited to premenopausal women only. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [3]. The label caps use at 8 doses per month and includes a warning about transient increases in blood pressure. Patients should not use more than one injection in a 24-hour period. The label also advises discontinuation if no improvement occurs after 8 weeks of use [3].

EMA Regulatory Pathway: Why Europe Took a Different Path

The EMA did not grant marketing authorization for bremelanotide. Palatin Technologies and its licensing partners pursued a different regulatory strategy in Europe, and the drug never completed the centralized marketing authorization procedure through the Committee for Medicinal Products for Human Use (CHMP).

Evidentiary Thresholds Differ

Several factors explain the divergence. The EMA has historically applied a more conservative risk-benefit framework to drugs for female sexual dysfunction. When flibanserin (Addyi) was evaluated, the EMA's CHMP rejected its application in 2010, concluding that the benefits did not outweigh the risks [4]. This set a precedent: the bar for demonstrating clinically meaningful improvement in HSDD-related endpoints was perceived as higher in Europe.

Cardiovascular Concerns Weighed Differently

The transient blood pressure increases observed with bremelanotide likely factored into the calculus. In the RECONNECT trials, bremelanotide raised systolic blood pressure by an average of 2.5 mmHg and diastolic by 1.8 mmHg, with heart rate increasing by approximately 3 bpm, peaking about 2 to 3 hours post-dose [1]. For the FDA, these changes were manageable within a contraindicated population framework. European regulators tend to weigh population-level cardiovascular risk more heavily, particularly for a condition that is not life-threatening.

No Formal CHMP Rejection on Record

It is important to distinguish between a formal CHMP rejection (as occurred with flibanserin) and the absence of a completed application. Palatin Technologies did not receive a negative opinion from the CHMP because the company chose not to pursue authorization through that pathway to completion [5]. The commercial viability of the European market, combined with regulatory signals, appears to have influenced this strategic decision.

The Vyleesi Label: What Prescribers Need to Know

The FDA-approved prescribing information for Vyleesi runs 19 pages and contains specific clinical guidance that reflects the regulatory compromises made during the approval process [3].

Dosing and Administration Details

Each autoinjector delivers a fixed 1.75 mg dose of bremelanotide in 0.3 mL. Patients inject subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The drug reaches peak plasma concentration (Tmax) at approximately 1 hour, with an elimination half-life of 2.7 hours [3]. Onset of effect in the clinical trials was reported as early as 30 minutes post-injection in some patients, though the label recommends a 45-minute lead time.

Boxed Warning Absent, but Warnings Present

Vyleesi does not carry a boxed warning. It does, however, include warnings and precautions for: transient increases in blood pressure (mean systolic increase of 2.5 mmHg), focal hyperpigmentation (reported in 1% of patients, particularly those with darker skin tones), and nausea, which was the most common adverse event at 40% incidence versus 1% with placebo [3]. Nausea was also the primary reason for treatment discontinuation, with 7.6% of bremelanotide-treated patients stopping due to nausea [1].

The Nausea Problem

Nausea affected 40% of patients in the RECONNECT trials. That number stands out. An antiemetic pretreatment strategy is not formally recommended in the label, but clinical practice has trended toward ondansetron co-administration in some patients. Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trials, noted: "The nausea tends to diminish with repeated dosing in most women, and it is typically mild to moderate in severity, but it is the single largest barrier to adherence" [6].

Safety Signals: Cardiovascular and Dermatologic Findings

Both the FDA and potential European regulatory review focused heavily on two safety domains: cardiovascular effects and skin hyperpigmentation.

Blood Pressure and Heart Rate

The transient hemodynamic effects of bremelanotide are pharmacologically predictable. As a melanocortin-4 receptor agonist, bremelanotide activates pathways in the central nervous system that influence autonomic cardiovascular regulation [7]. In the RECONNECT pooled safety data, the mean peak systolic blood pressure increase was 2.5 mmHg, with individual patients occasionally exceeding 10 mmHg increases [1]. Blood pressure returned to baseline within 12 hours in the vast majority of subjects.

The FDA addressed this by contrainddicating Vyleesi in uncontrolled hypertension and cardiovascular disease. The EMA approach to similar hemodynamic signals in other drug classes (such as triptans and sympathomimetics) has generally demanded longer-term cardiovascular outcome data before granting broad population access, particularly when the target condition is non-life-threatening [4].

Hyperpigmentation

Bremelanotide activates melanocortin-1 receptors (MC1R), which regulate melanin synthesis. In clinical trials, 1% of patients developed focal areas of darkened skin, most commonly on the face, gingiva, or breasts [3]. The hyperpigmentation was not fully reversible in all cases at the time of trial completion. This finding, while uncommon, raises questions about the cosmetic acceptability and long-term dermatologic safety of repeated dosing over years.

Post-Market Surveillance Requirements

The FDA required Palatin Technologies to conduct a post-marketing observational study (PMR 3326-1) to assess the risk of cardiovascular events, hyperpigmentation persistence, and patterns of real-world use including off-label prescribing [3]. The FDA Sentinel System also monitors claims-based safety data for bremelanotide. As of 2025, no new safety signals have emerged that would alter the approved labeling [8].

Comparing Regulatory Philosophy: FDA vs EMA on Female Sexual Dysfunction

The bremelanotide case illustrates a broader pattern in how the two agencies evaluate drugs for HSDD and related conditions.

The Flibanserin Precedent

Flibanserin (Addyi) was rejected by the FDA twice before gaining approval in 2015 under pressure from patient advocacy groups and an FDA advisory committee that voted 18-6 in favor [9]. The EMA rejected flibanserin in 2010, and it has never been approved in Europe [4]. The FDA's eventual approval of flibanserin created a regulatory environment more receptive to subsequent HSDD treatments, including bremelanotide.

Benefit-Risk Frameworks

The FDA uses a structured benefit-risk framework that explicitly considers the severity of the condition, available alternatives, and patient perspectives. For HSDD, the FDA heard testimony from patient advocacy organizations arguing that the lack of approved treatments for women represented a gender disparity in sexual medicine [2]. The EMA's CHMP evaluates similar factors but has not historically weighted patient advocacy input in the same way during the opinion-forming process.

Regulatory Arbitrage in Practice

The practical result is that bremelanotide is available in the United States and several other markets that reference FDA approvals, but not in EU member states. Women in Europe with HSDD have access to flibanserin in some countries through national-level mechanisms, but neither FDA-approved HSDD drug holds EMA centralized authorization [4]. This creates a two-tier access field for female sexual dysfunction pharmacotherapy.

Clinical Pharmacology: How Bremelanotide Works

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds with high affinity to melanocortin-4 receptors (MC4R) and melanocortin-1 receptors (MC1R) [7].

Mechanism in Sexual Desire

The MC4R pathway in the hypothalamus and limbic system modulates sexual arousal and desire through dopaminergic and oxytocinergic signaling [7]. Animal models demonstrated that MC4R activation increased solicitation behaviors in female rats independent of estrogen status, suggesting a central rather than peripheral mechanism of action [10]. This pharmacology differentiates bremelanotide from flibanserin, which acts primarily on serotonin receptors (5-HT1A agonist, 5-HT2A antagonist).

Pharmacokinetic Profile

Following subcutaneous injection of 1.75 mg, bremelanotide reaches Cmax of approximately 80 ng/mL at 1 hour post-dose [3]. Bioavailability is approximately 100% by the subcutaneous route. The drug is metabolized by hydrolysis to inactive peptide fragments, with renal clearance accounting for roughly 65% of elimination. No hepatic CYP450 interactions have been identified, which simplifies co-prescribing [3].

Drug Interactions

The label notes that bremelanotide slowed gastric emptying in clinical studies, which may affect absorption of orally administered medications [3]. Patients taking oral naltrexone experienced a 25% reduction in naltrexone exposure when co-administered with bremelanotide. No clinically significant interactions were found with sildenafil, combined oral contraceptives, or alcohol [3].

Real-World Utilization and Market Performance

Vyleesi launch performance has been modest compared to initial commercial projections.

Prescribing Patterns

IQVIA prescription data from 2020 through 2024 shows that Vyleesi never exceeded 5,000 total prescriptions per quarter in the US market [11]. Multiple factors explain the slow uptake: the subcutaneous injection route, the 40% nausea rate, limited insurance coverage, and out-of-pocket costs that ranged from $800 to $950 per carton of 4 autoinjectors at launch [11].

Corporate Transitions

AMAG Pharmaceuticals, which held US commercial rights, was acquired by Covis Pharma Group in 2020. Covis subsequently scaled back direct-to-consumer marketing spend. Palatin Technologies retained rights for future formulation development, including investigation of an intranasal delivery route that could address both the injection barrier and potentially the nausea issue by altering the pharmacokinetic profile [5].

Insurance and Access

Most commercial insurers classify Vyleesi as a specialty medication requiring prior authorization. Step therapy through flibanserin is commonly required before Vyleesi approval. Medicare Part D does not cover Vyleesi because it falls under the Part D exclusion for drugs used for sexual dysfunction or erectile dysfunction under Section 1860D-2(e)(2)(A) [12].

What a Future EMA Application Would Require

If a manufacturer were to pursue EMA authorization for bremelanotide in the future, several additional data packages would likely be expected.

Cardiovascular Outcome Data

The CHMP would probably require a dedicated cardiovascular safety study, or at minimum, a comprehensive meta-analysis of hemodynamic data from all completed trials plus post-market surveillance. A study powered to rule out a meaningful increase in major adverse cardiovascular events (MACE) would be the gold standard, though the practical feasibility of such a trial for an as-needed HSDD medication is questionable.

Long-Term Hyperpigmentation Data

European regulators would want longer follow-up on the reversibility of MC1R-mediated hyperpigmentation, potentially requiring a dermatologic substudy with objective melanin index measurements over 12 to 24 months post-discontinuation.

Health-Related Quality of Life

The EMA has increasingly emphasized patient-reported outcomes that map to validated quality-of-life instruments beyond disease-specific scales. The FSDS-DAO, while accepted by the FDA, might need supplementation with a generic health utility measure such as the EQ-5D to satisfy CHMP expectations for a benefit-risk assessment in a non-life-threatening condition.